Showing 1781-1790 of 8885 results for "".
Risk Factor: Characterizing Melanoma Risk Clinically
https://practicaldermatology.com/topics/practice-management/risk-factor-characterizing-melanoma-risk-clinically/20844/Can clinical features help determine an individual's melanoma risk?Cash Flow: Beyond the Basics
https://practicaldermatology.com/topics/practice-management/cash-flow-beyond-the-basics/20846/How to use cash flow to your advantage and maximize business capital.Benchside Dispatches: Pruritus
https://practicaldermatology.com/topics/practice-management/benchside-dispatches-pruritus/20926/An interview with Gil Yosipovitch, MDBreaking the Red Tape: The AMA and Meaningful Use
https://practicaldermatology.com/topics/practice-management/breaking-the-red-tape-the-ama-and-meaningful-use/21096/Therapeutics Focus: Fungal Infections
https://practicaldermatology.com/topics/practice-management/therapeutics-focus-fungal-infections/21184/Raising Issues with MOC
https://practicaldermatology.com/topics/practice-management/raising-issues-with-moc/21195/Dermatologists and the AAD speak out against current MOC requirements and suggest changes.The Melanoma Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-melanoma-pipeline/21400/A closer look at the latest data for two investigational agents that have made headlines.Weighing the Prospects of Biosimilars
https://practicaldermatology.com/columns/clinical-focus-1/weighing-the-prospects-of-biosimilars/21477/If they are found to be comparable to the “originators,” biosimilar agents may offer patients significant therapeutic benefits as well as cost efficiency.EHR User Series—Part III
https://practicaldermatology.com/topics/practice-management/ehr-user-seriespart-iii/21509/A Q&A series with clinicians about their experience and broader impressions of EHRs in dermatology.Hyperpigmentation in Darker Skin Types: A Review of Current Treatments
https://practicaldermatology.com/programs/practical-dermatology/hyperpigmentation-in-darker-skin-types-a-review-of-current-treatments/24217/Pigmentary disorders are a leading concern for patients and consumers worldwide.